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A B S T R A C T
Objectives: Tumor associated fibroblasts (TAFs) are essential contributors of the progression of non-small cell
lung cancer (NSCLC). Most lung TAFs exhibit an activated phenotype characterized by the expression of α-SMA
and fibrillar collagens. However, the prognostic value of these activation markers in NSCLC remains unclear.
Material and Methods: We conducted a quantitative image analysis of α-SMA immunostaining and picrosirius red
staining of fibrillar collagens imaged by bright-field and polarized microscopy, respectively, using tissue mi-
croarrays with samples from 220 surgical patients, which elicited a percentage of positive staining area for each
marker and patient.
Results: Kaplan-Meier curves showed that all TAF activation markers were significantly associated with poor
survival, and their prognostic value was independent of TNM staging as revealed by multivariate analysis, which
elicited an adjusted increased risk of death after 3 years of 129% and 94% for fibrillar collagens imaged with
bright-field (p= 0.004) and polarized light (p= 0.003), respectively, and of 89% for α-SMA (p= 0.009). We
also found a significant association between all TAF activation markers and tumor necrosis, which is often
indicative of hypoxia, supporting a pathologic link between tumor desmoplasia and necrosis/hypoxia.
Conclusions: Our findings identify patients with large histologic coverage of fibrillar collagens and α-
SMA+TAFs to be at higher risk of recurrence and death, supporting that they could be considered for adjuvant
therapy.
https://doi.org/10.1016/j.lungcan.2019.07.020
Received 11 October 2018; Received in revised form 18 June 2019; Accepted 22 July 2019
Abbreviations: ADC, adenocarcinoma; α-SMA, alpha smooth muscle actin; BF, brightfield; HR, hazard ratio; LCC, large cell carcinoma; OS, overall survival; PL,
polarized light; PSR, picrosirius red; SCC, squamous cell carcinoma; TAF, tumor-associated fibroblast; TMA, tissue microarray
⁎ Corresponding author at: Unit of Biophysics and Bioengineering, Department of Biomedicine, School of Medicine and Health Sciences, Universitat de Barcelona,
Barcelona, Spain.
E-mail address: jalcaraz@ub.edu (J. Alcaraz).
Lung Cancer 135 (2019) 151–160
0169-5002/ © 2020 Published by Elsevier B.V.
T
1. Introduction
Lung cancer is the leading cause of cancer-related death in both men
and women worldwide, with an overall 5 year survival rate of 18%
[1,2]. This leading position is partly associated with the fact that most
lung cancer patients remain undiagnosed until the disease is sympto-
matic and has reached an advanced stage [3]. Surgically-treated pa-
tients tend to exhibit better prognosis, particularly when diagnosed at
early stages, but still have a suboptimal potential cure of only ˜30-50%
[1].
Histologically, non-small cell lung cancer (NSCLC) is diagnosed in
up to 90% of lung cancer patients, and adenocarcinoma (ADC) and
squamous cell carcinoma (SCC) are the major subtypes [1]. Because
these lung cancer subtypes are epithelial in origin, most previous stu-
dies have focused on the pathologic features of lung carcinoma cells.
However, it is increasingly acknowledged the prominent role of the stiff
desmoplastic tumor stroma that surrounds carcinoma cells in the pro-
gression of lung cancer and other solid tumors [4]. This desmoplastic
stroma is rich in activated fibroblasts (referred to as cancer- or tumor-
associated fibroblasts (TAFs)), infiltrated immune cells and other less
frequent cell types, in the background of an abundant deposition of
fibrillar collagens and other fibrotic extracellular matrix components
[4,5]. Of note, TAFs are largely responsible for the aberrant stromal
deposition of fibrillar collagens within the tumor stroma [6], and are
receiving increasing interest as a therapeutic target [7], as illustrated by
the recent approval of the antiangiogenic and antifibrotic drug ninte-
danib to treat lung ADC patients in combination with docetaxel [8,9].
In addition to their therapeutic relevance, studies in vitro have re-
ported the prognostic value of epigenetic and transcriptional signatures
associated with pulmonary TAFs [10,11]. In contrast, little is known on
the clinical relevance of standard markers of activated fibroblasts in
histologic samples from NSCLC patients. Thus very few studies have
examined the prognostic value of stromal alpha-smooth muscle actin
(α-SMA) in lung cancer, which is the gold standard marker of fibroblast
activation [12]; moreover these studies have reported contradictory
results [13,14], underscoring that the prognostic value of α-SMA in
NSCLC remains unclear. In addition to α-SMA, the deposition of fibrillar
(type I and III) collagens is another common marker of activated fi-
broblasts; however, to our knowledge their prognostic value in NSCLC
has not been determined. To address this gap of knowledge we con-
ducted a retrospective multicenter study of the prognostic value of
standard markers of activated fibroblasts in using tissue microarrays
(TMAs) containing samples from a cohort of early stage surgically-
treated NSCLC patients gathered from multiple hospitals in Spain [15].
For this purpose we performed a quantitative image analysis of both α-
SMA immunostaining and picrosirius red (PSR) staining of fibrillar
collagens imaged with bright field and polarized microscopy, respec-
tively, and combined these data with clinical information including
survival gathered within a 3 year follow-up.
2. Materials and methods
2.1. Patients and tissue samples
This study involved the retrospective analysis of tissue samples from
surgical patients collected by multiple Spanish hospitals belonging to
the Bronchogenic Carcinoma Cooperative Group of the Spanish Society
of Pneumology and Thoracic Surgery (GCCB-S) [15], as part of their
contribution to the 8th edition of the IASLC staging project [16]. The
initial cohort included 220 patients that were observed during a
minimum of 3 years. Eighty-three patients died within the three years
after surgery (39.7%). Histologic diagnosis and staging was conducted
in accordance with the 8th edition of the IASLC staging project [17].
The initially gathered clinicopathologic variables are described else-
where [18], and included smoking status, comorbidities, blood ana-
lyses, tumor location, staging, lung function, surgical treatment,
pathological diagnosis and PET imaging. Survival was assessed yearly.
The experimental protocol was approved by the Ethics Committee of
the study (Fundació Parc Taulí, PI12/02040) and by the Ethics Com-
mittees of all participating centers. Written informed consent was ob-
tained from all patients.
2.2. Tissue microarray construction
Formalin-fixed paraffin embedded tissue samples were obtained
from participating hospitals and stored at the CIBERES Pulmonary
Biobank Platform (PBP). Three expert pathologists evaluated the sam-
ples, confirmed the histologic diagnosis and selected a representative
tumor area for core extraction and subsequent Tissue Microarray (TMA)
analysis. TMAs were prepared at the Morphology Core Facility at the
Center for Applied Medical Research (CIMA) of the University of
Navarra (Pamplona, Spain). TMAs were constructed using a manual
tissue arrayer (MTA-1, Beecher Instruments). Three cylinders of 1mm
in diameter were obtained within a representative tumor region for
each tumor sample, cut in 3 μm sections with a microtome (Microm,
HM350S), and distributed as 3 sections per sample. Each TMA included
samples from either ADC, SCC or other histologic subtypes, and were
stored in paraffin until use.
2.3. Histology
Fibrillar collagens were stained with PSR, whereas α-SMA and Ki-67
were stained by immunohistochemistry. α-SMA and PSR stainings were
conducted with the Bond automated system (Leica Microsystems) as
described [19,20]. Nuclei were counterstained with hematoxylin. α-
SMA, PSR and Ki-67 were visualized with bright field illumination with
an upright microscope (BX43, Olympus) coupled to a digital camera
(DP72, Olympus) using a 10× objective (Olympus). PSR staining was
also imaged with an upright microscope (DMRB, Leica) equipped with
polarized filters coupled to a digital camera (DFC450, Leica) using a
10×/0.25 NPlan objective (Leica). Vascular invasion (arterial or ve-
nous) was assessed by examining morphological infiltration of vein
walls in H&E stainings.
2.4. Image analysis
All image processing was carried out with Image J [21] under the
guidance of one of our pathologists (JR). Large void regions were
manually removed to prevent overestimating the total area. For bright
field images, each raw file was color deconvoluted ―using either H-
DAB (for α-SMA) or FastRed FastBlue DAB (for PSR)― and the suitable
color channel was binarized and used to calculate the positive area
fraction (%) over the total sample area (Suppl. Fig. S1). Area fraction
was averaged for all images per patient (n=3) to elicit the final patient
percentage as α-SMA% or PSR-BF% (for PSR imaged with bright field).
α-SMA images were also used to assess the percentage of necrotic area
for each patient by manually outlining the necrotic regions and com-
puting the corresponding area fraction. Similarly, images of PSR
staining visualized with polarized light (PSR-PL) were converted into
greyscale, inverted, binarized and used to compute the percentage (%)
of positive area, which was averaged for each patient to elicit the final
percentage as PSR-PL%. The number of positively stained nuclei for Ki-
67 was counted and expressed as a percentage (Ki-67%) as described
[20].
2.5. Statistical analysis
All statistical analyses were performed with the widely-used com-
puting environment R-software, using computing functions of the base,
survival, survivalROC and coin packages. Overall survival functions
were assessed using the Kaplan-Meier estimator. Survival curves were
compared by applying the Tarone-Ware test. Association between
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quantitative variables was assessed by the Pearson’s or Spearman cor-
relation coefficient as required. Association between qualititative
variables was evaluated by the chi-square test. When the applicability
conditions were not met, Fisher’s exact test was used. Comparisons of
means were performed by Student’s t-test. For each marker, optimum
thresholds were computed by maximising the Youden’s index J, which
is defined as J = Sensitivity+ Specificity – 1 [22,23]. Adjusted hazard
ratios were estimated by fitting the Cox’s proportional hazards regres-
sion model as described in the main text. P-values were determined by
likelihood ratio test and score test. Statistical significance was assumed
at p < 0.05, whereas p < 0.1 was interpreted as marginally sig-
nificant.
3. Results
3.1. Description of clinicopathologic data
We analyzed retrospectively TMAs containing samples from a co-
hort of 220 surgical patients gathered from multiple hospitals in Spain,
which were observed during a minimum of 3 years. TMAs included
samples from 3 representative tumor regions for each patient. The
clinicopathologic features of our cohort and their overall survival (OS
%) 3 years after surgery are shown in Table 1. The median patient age
at the day of surgery was 66.2 years, with a range of 31.5–85.0 years,
and the OS% was 60.3%. Most patients were male (85.6%) with a
history of smoking as former (48.6%) or current (41.8%) smokers. Very
few patients had a weight loss in the previous 6 months greater than
5 kg (8.7%); in contrast, nearly half (43.3%) had a cardiac comorbidity.
The histological distribution was 50.2% ADC, 44.0% SCC and 5.7%
large cell carcinoma (including both large cell carcinomas (2.4%) and
large cell neuroendocrine carcinomas (3.3%)). Most patients exhibited
a well or moderately well-differentiated histologic grade (74.8%), and
their clinical TNM stage distribution declined with increasing stage
(50.9% stage I, 34.5% stage II, 14.1% stage III and 0.5% stage IV).
Histologic analysis revealed that vascular invasion was not observed in
most patients (69.8%). As expected, the association between OS% (as-
sessed 3 years after surgery here and thereafter) and the TNM stage was
statistically significant (p < 0.001) [17]. In addition OS% was asso-
ciated with cardiac comorbidity, although with marginal significance (p
= 0.07).
3.2. Expression of fibroblast activation markers and their correlations
Even though collagen can be visualized with different histologic
stainings, picrosirius red (PSR) has been pointed as the most specific for
fibrillar collagens, for it enhances selectively the birefringence of col-
lagen fibers, thereby rendering them visible with polarized microscopy
[24,25]. Representative images of α-SMA and PSR stainings illustrating
different coverage levels are shown in Fig. 1 and Suppl. Fig. S2. PSR
revealed that stromal fibrillar collagens were often organized into thick
layers surrounding groups of carcinoma cells. In agreement with the
unique optical features of PSR, the fibrillar nature of collagen was more
readily observable using polarized light than bright field illumination as
shown in Fig. 1. Images of α-SMA staining revealed that it was localized
in the cytoplasm and was largely restricted to stromal regions, as in-
dicated by the visual overlap with PSR staining (Fig. 1 and Suppl. Fig.
S2). Subsequent image processing enabled computing the percentage of
positive area per image collected for each patient for either α-SMA (α-
SMA%) or PSR imaged with bright field or polarized light ― referred to
as PSR-BF% and PSR-PL%, respectively― (Suppl. Fig. S1.). This image
processing revealed that the positive area of PSR staining was generally
larger with bright field than polarized light (Suppl. Fig. S1), which il-
lustrates the known fact that linearly polarized light captures only a
fraction of the total content of fibrillar collagens [24,25]. In addition, a
strong positive correlation between PSR-BF% and PSR-PL% (r= 0.79,
p < 0.001, Pearson´s correlation coefficient) was observed, in agree-
ment with previous observations [25]. Likewise we found a highly
significant positive correlation between α-SMA% and either PSR-BF%
(r= 0.40, p < 0.001) or PSR-PL% (r = 0.26, p < 0.001) (Suppl. Fig.
S3), which is consistent with the common use of both α-SMA and fi-
brillar collagens as markers of activated fibroblasts.
3.3. Association of fibroblast activation markers with clinicopathologic
variables
To analyze the association of α-SMA% and PSR% (which refers to
both PSR-BF% and PSR-PL% here and thereafter) with clin-
icopathologic variables, we first identified a suitable threshold for each
marker by maximising the Youden´s index, which gives equal weight to
both the marker´s sensitivity and specificity [22,23]. This method is
widely used in the diagnostic biomarker field, and is equivalent to the
minimization of the sum of false negative and false positive rates, which
is clinically appealing because it maximizes the overall correct diag-
nosis rate while minimizing the overall erroneous diagnosis rate [26].
This approach elicited two threshold candidates for α-SMA% and PSR-
BF% that corresponded to two separate maximum in the Youden´s
index for these markers (i.e. 10.5% and 15.2% for α-SMA%, and 7.9%
and 16.80% for PSR-BF%) and one threshold for PSR-PL% (3.29%)
(Suppl. Fig. S4). The lower thresholds for α-SMA% and PSR-BF%
Table 1
Cumulative OS% rates (36 months) of clinicopathologic variables.
Clinical variable n (%) OS (%) p-value
Age (y.o.)
< 65 90 (43.3%) 65.0 0.12
≥65 118 (56.7%) 56.3
Gender
Female 30 (14.4%) 70.0 0.38
Male 178 (85.6%) 58.3
Race
Caucasian 208 (100%) 60.3 n.a.
Other 0 n.a.
Smoking history
Never 20 (9.6%) 55.0 0.40
Former 101 (48.6%) 57.9
Current 87 (41.8%) 63.7
Weight loss
absent (≤5 Kg) 190 (91.3%) 61.2 0.15
present (> 5 Kg) 18 (8.7%) 47.2
Cardiovascular comorbidity
No 118 (56.7%) 64.7 0.066
Yes 90 (43.3%) 54.0
Histologic subtype
Adenocarcinoma 105 (50.2%) 62.9 0.34
Squamous cell carcinoma 92 (44.0%) 55.6
Large cell carcinoma 12 (5.7%) 74.1
Differentiation grade
Well/mod. differentiated (G1,G2) 151 (74.8%) 58.9 0.91
Poorly differentiated (G3) 51 (25.2%) 62.9
Tumor stage (TNM)a
IA1 6 (2.9%) 50.0 <0.001*
IA2 21 (10.2%) 71.4
IA3 31 (15.0%) 71.0
IB 47 (22.8%) 82.4
IIA 15 (7.3%) 60.0
IIB 56 (27.2%) 55.7
IIIA 29 (14.1%) 14.9
IVA 1 (0.5%) 0.0
Vascular invasion
No (V0) 118 (69.8%) 60.4 0.23
Yes microscopic (V1) 49 (29.0%) 57.7
Yes macroscopic (V2) 2 (1.2%) 0.0
NOTE:
n.a.: not available.
Bold p-values indicate marginal significance (p < 0.1).
* p < 0.05 (log-rank test).
a According to 8th edition of the IASLC staging classification.
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exhibited the highest sensitivity, whereas the corresponding higher
thresholds exhibited the highest specificity (Suppl. Fig. S4). In agree-
ment with previous work [27], we selected the lower thresholds (i.e.
10.5% for α-SMA%, 7.9% for PSR-BF% and 3.3% for PSR-PL%) for
subsequent analyses, and used them in the main figures, whereas those
analyses carried out with the alternative (higher) thresholds (i.e. 15.2%
for α-SMA%, 16.8% for PSR-BF% and 3.3% for PSR-PL%) are shown in
Suppl. Fig. S5-S6 and Suppl. Tables S1-S2.
Clinicopathologic variables stratified by α-SMA%, PSR-BF% and
PSR-PL% according to the latter thresholds are shown in Table 2. We
found a significant association between PSR-BF% and both smoking
history (p= 0.01) and histologic classification (p < 0.001). Further-
more, PSR-BF% was marginally associated with the maximum stan-
dardized uptake value (SUVmax) assessed by 18F-fluorodeoxyglucose
Fig. 1. Histologic images of standard fibroblast activation markers in NSCLC.
Representative images of histologic samples within TMAs of patients exhibiting either low, intermediate or large coverage of the stainings of TAF activation markers
α-SMA and fibrillar collagens. The latter were stained with picrosirius red (PSR). α-SMA and PSR were imaged with bright-field microscopy (left and middle
columns). PSR was further imaged with polarized microscopy (right column). Stars indicate necrotic areas used for subsequent analyses. Scale bars, 100 μm.
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positron emission tomography, which is indicative of the regional
glucose uptake in the primary tumor, yielding 11.0 ± 6.1 for PSR-BF
%>8% and 9.1 ± 5.9 for PSR-BF% ≤ 8% (p= 0.069). In contrast,
no further associations were observed between other TAF activation
markers and any other clinicopathologic variable. Thus, despite the
significant correlations between all activation markers, only PSR-BF%
was significantly associated with selected clinicopathologic data,
thereby supporting that distinct TAF activation markers may be in-
dicative of somewhat distinct features of the desmoplastic tumor
stroma.
3.4. Association of fibroblast activation markers with overall survival OS%
The thresholds described in the previous section were used as cut-
offs to assess the Kaplan-Meier survival curves for each fibroblast ac-
tivation marker. Remarkably, the group of patients with high levels of
the activation markers (i.e. above the cut-off) consistently exhibited
lower survival with statistical significance, including α-SMA% (p=
0.04, log-rank test), PSR-BF% (p= 0.009) and PSR-PL% (p= 0.004)
(Fig. 2). These findings reveal that the histologic coverage of both α-
SMA and fibrillar collagens within the desmoplastic stroma are asso-
ciated with poor prognosis in NSCLC, and identify that PSR analyzed
through polarized light microscopy is particularly useful in terms of
predicting poor outcome.
To discern whether the prognostic value of TAF activation markers
is already captured by the current gold standard of tumor staging based
on TNM, we introduced either α-SMA%, PSR-BF% or PSR-PL% and
tumor stage in a Cox regression model for multivariate OS% analysis.
Given the close relationship between OS% and cardiac comorbidity
reported in Table 1, we also included the latter variable in the analysis.
Of note, all TAF activation markers were independent prognostic fac-
tors, with the largest significance found in fibrillar collagens (PSR-BF%,
p= 0.008 (likelihood ratio test); PSR-PL%, p= 0.004) compared to α-
SMA% (p= 0.049). The results of the multivariate analysis are shown
in Table 3, and revealed that patients with PSR-BF% above the cut-off
(8%) had an adjusted 129% increased risk of death (HR=2.29; 95%
CI, 1.33–3.97; p= 0.004). Similarly, those patients with PSR-PL%
larger than the cut-off (3.3%) had 94% increased risk of death (HR =
1.94; 95% CI, 1.26–2.99; p= 0.003), whereas patients with α-SMA%
larger than the 10.5% cut-off had 89% increased risk of death (HR =
1.89; 95% CI, 1.17–3.04; p= 0.009). Cardiac comorbidity was also a
significant independent prognostic factor for all markers, in agreement
with previous reports [28]. These results reveal that the adjusted in-
creased risk of death associated with the histologic coverage of either α-
SMA or fibrillar collagens analyzed by PSR staining does not depend on
a particular stage. In contrast, a multivariate analysis with an expanded
list of clinicopathological variables (Age, Smoking history, Histologic
subtype, and Vascular invasion) did not reveal additional independent
prognostic factor consistently across the 3 stromal variables examined
(Suppl. Table S3).
3.5. Association of fibrillar collagens with cancer-relevant
pathophysiological processes
Once established the prognostic value of standard TAF activation
markers in NSCLC, we began to examine potential underlying
Table 2
Association between TAF activation markers and clinicopathologic variables.
clinical variable α-SMA% > 10.5% PSR-BF% > 8% PSR-PL% > 3.3%
Percentage p-value Percentage p-value Percentage p-value
Age (y.o.)
< 65 60.2% 0.65 74.7% 0.81 50.0% 0.64
≥65 64.5% 72.2% 54.3%
Gender
Female 62.1% 1.00 86.7% 0.12 63.3% 0.27
Male 62.7% 70.9% 50.6%
Smoking history
No (never) 57.9% 0.84 100.0% 0.010* 70.0% 0.16
Yes (former, current) 63.2% 70.3% 50.5%
Weight loss
absent (≤5 Kg) 62.9% 1.00 73.0% 1.0 51.3% 0.42
present (> 5 Kg) 60.0% 76.5% 64.7%
Cardiovascular comorbidity
No 66.4% 0.27 75.4% 0.53 53.0% 0.96
Yes 57.5% 70.5% 51.7%
Histologic subtype
Adenocarcinoma 60.0% 0.52 84.0% <0.001* 53.9% 0.75
Squamous cell carcinoma 65.6% 64.8% 49.5%
Large cell carcinoma n.a. 41.7% 58.3%
Differentiation grade
Well/mod. differentiated (G1,G2) 63.9% 0.65 75.3% 0.78 54.1% 0.41
Poorly differentiated (G3) 58.7% 72.0% 46.0%
Tumor stage (TNM)
IA1 40.0% 0.66 80.0% 0.99 80.0% 0.83
IA2 78.9% 76.2% 57.1%
IA3 57.7% 77.4% 48.4%
IB 63.6% 73.3% 47.8%
IIA 66.7% 73.3% 60.0%
IIB 56.6% 69.1% 49.1%
IIIA 65.4% 74.1% 57.1%
IVA 100.0% 100.0% 100.0%
Vascular invasion
No (V0) 67.3% 0.40 77.2% 0.39 59.6% 0.18
Yes (V1, V2) 58.7% 69.4% 47.1%
Bold p-values indicate marginal significance (p < 0.1).
* p < 0.05 (χ2 test).
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pathophysiological processes. Our observed association between PSR-
BF% and the regional glucose uptake (SUVT) prompted us to examine a
potential association with proliferation by analyzing Ki-67 staining. In
addition, we examined other tumor-promoting biological processes
previously associated with increased fibrillar collagens, including in-
vasion and hypoxia [5], by analyzing quantitatively vascular invasion
and tumor necrosis, respectively, for necrosis is frequently used as a
surrogate marker of hypoxia [29]. The information on vascular invasion
was initially gathered in our clinicopathologic dataset, whereas both Ki-
67 and necrosis were assessed as percentage of positive area by quan-
titative image analysis of α-SMA stainings as shown in Fig. 1, and were
referred to as Ki-67% and necrosis%, respectively. Of note, all TAF
activation markers consistently showed a significant positive associa-
tion with necrosis% as indicated in Fig. 3 (α-SMA%, p < 0.001; PSR-
BF%, p= 0.02; PSR-PL%, p= 0.03). In contrast no significant asso-
ciations were found between Ki-67% or vascular invasion and any of
the TAF activation markers. These results reveal a novel strong asso-
ciation between the extent of TAF activation, tumor necrosis and poor
survival in surgical NSCLC patients.
Finally we examined to what extent the observations reported here
were specific for the particular threshold selection that maximized the
Youden´s index by re-analyzing the data using the alternative thresh-
olds for α-SMA% (15.5%) and PSR-BF% (17%), which exhibit max-
imum specificity rather than sensitivity (Suppl. Fig. S4). In agreement
with our initial findings, stratifying patients for each TAF marker ac-
cording to the alternative thresholds elicited significant associations
with both poor survival (Suppl. Table S2 and Suppl. Fig. S5) and ne-
crosis (Suppl. Fig. S6), although the association between PSR-BF% and
survival was marginally significant. Indeed, we only found minor dif-
ferences in terms of fewer associations with clinicopathologic data
(Suppl. Table S1) when using the alternative cut-offs, thereby re-
assuring that all thresholds obtained through the maximization of
Youden´s index provided consistent results.
4. Discussion
A hallmark of NSCLC and other solid tumors is the presence of a stiff
desmoplastic stroma rich in activated TAFs in the background of an
excessive deposition of fibrillar collagens [5]. Stromal TAFs have been
implicated in virtually all steps of tumor progression [7]. Therefore it is
unsurprising that stromal proteins, including those related to TAFs, are
receiving increasing interest as biomarkers or therapeutic targets
[9,30]. However, the prognostic value of standard markers of activated
TAFs had remained ill defined in NSCLC. Thus, the prognostic value of
α-SMA had remained unclear due to conflicting observations [13,14],
whereas that of fibrillar collagens has not been assessed directly.
Using a cohort of 220 NSCLC patients, we found that stromal α-
SMA, assessed by quantitative image analysis, was significantly asso-
ciated with shorter survival 3 years after surgery, and that this prog-
nostic value was independent of TNM staging. In agreement with our
findings, a histologic α-SMA scoring study conducted in China on a
smaller cohort (n=78) reported an association with adverse prognosis
[14]. In contrast, a lack of association between α-SMA scoring and
survival was reported in a study carried out in Norway with a larger
cohort (n=536) [13]. The reasons underlying the discrepancy of the
Norwegian study compared to the Chinese study and ours are unclear.
However it is conceivable that this discrepancy may be associated with
the different methodologies used to analyze stromal α-SMA, since the
Norwegian study used a single semi-quantitative scoring based on the
percentage of positive stromal cells [13], whereas the Chinese study
used the multiplication a percentage score and an intensity score [14].
In further agreement with our observations, positive correlations be-
tween higher stromal α-SMA and different markers of tumor progres-
sion have been reported in breast cancer [31] and gastric carcinoma
[32]. In contrast, α-SMA expression was found not associated with
survival in head and neck squamous cell carcinoma [33]. Collectively,
Fig. 2. Survival analysis of NSCLC patients stratified according to standard fi-
broblast activation markers.
Kaplan-Meier survival curves stratifying patients according to α-SMA% (A),
PSR-BF% (B) and PSR-PL% (C). For each marker, the low and high expression
groups correspond to patients exhibiting a percentage of positive area below or
equal/greater than the threshold, respectively.
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our data and previous observations support that stromal α-SMA is as-
sociated with poor outcome in NSCLC, and underline that a consensus
method for α-SMA scoring is needed to confirm its prognostic value in
other cancer types.
To our knowledge our study reports for the first time that the his-
tologic coverage of stromal fibrillar collagens ―assessed by image
analysis of PSR staining with bright-field or polarized light― is a risk
factor for increased death in resected NSCLC patients. Remarkably, the
prognostic value of PSR was independent of TNM staging, indicating
that PSR staining of fibrillar collagens is a novel independent prognostic
biomarker in NSCLC. In support to our collagen analysis, a semi-
quantitative scoring of tumor collagen content by van Gieson staining
in a large cohort of NSCLC patients (n= 533) reported a trend between
high collagen and decreased progression-free survival that attained
marginal significance [30]. Likewise, indirect assessments of the col-
lagen content in NSCLC patients from H&E stainings reported an asso-
ciation with poor survival in SCC (n=220) [34] and ADC patients
(n=239) [35]. Altogether these observations indicate that the asso-
ciation between stromal collagen and adverse patient outcome is an
emerging hallmark of NSCLC, and expand previous links between
stromal collagen and increased risk of cancer [36,37]. More im-
portantly, our results reveal that the assessment of the fibrillar collagen
coverage in histologic samples by PSR staining may be a new clinical
tool to identify those resected patients that are at higher risk of pro-
gression and death after surgery. Likewise, our data support that as-
sessing the histologic coverage of fibrillar collagens may be a new
suitable marker to help selecting which resected patients should be
considered for adjuvant chemotherapy.
Stromal collagens can be stained with different methods, yet PSR
has been pointed as the most sensitive owing to its unique ability to
detect thin fibers [24,38]. PSR is also unique in that it changes the
optical properties of fibrillar collagens by enhancing their bi-
refringence, thereby allowing the direct visualization of fibers of type I
and III collagens with polarized light [25]. However, it had remained
unknown what visualization method of PSR (bright field or polarized
light) could be more useful in terms of prognosis. Of note, our quanti-
fication of PSR imaged with polarized light (PSR-PL%) elicited the
lowest p-values when analyzing survival data, thereby underlining that
this imaging technique is particularly useful when using PSR as a
prognostic biomarker. However, even though the specificity of PSR
imaged with polarized light to detect fibrillar collagens has been ex-
tensively validated in organ fibrosis [38], the use of this method in
NSCLC and other cancer types is still rather limited [19,39]. On the
other hand, PSR imaged with standard (non-polarized) bright-field
(PSR-BF%) reported more associations with clinicopathological vari-
ables than PSR-PL%, in agreement with previous observations [25],
thereby supporting that the combination of PSR visualization with both
imaging methods provides complementary information.
The expression of genes coding for type I collagen has been con-
sistently reported in transcriptional signatures associated with metas-
tasis and shorter survival in lung ADC and other cancer types [40].
These observations strongly suggest that fibrillar collagens may play an
active role in tumor progression in addition to being useful prognostic
biomarkers. Indeed, defining tumor-promoting effects of fibrillar col-
lagens is a matter of increasing research [5]. To begin to identify which
of the latter effects might be more relevant in NSCLC, we sought for
potential associations with three prevalent tumor-promoting biological
processes: vascular invasion, proliferation and necrosis/hypoxia. The
rationale for analyzing vascular invasion is based on previous studies
using intravital imaging that showed how cancer cells migrate more
rapidly in collagen-rich regions [41]. Likewise studies conducted in
breast cancer revealed that high collagen amount, particularly when
deposited radially from groups of carcinoma cells, promoted cancer cell
migration [42]. In contrast, we did not find significant differences be-
tween histologic vascular invasion when stratifying patients according
to their fibrillar collagen coverage. A possible interpretation of this
negative result is that it is the spatial organization of the collagen fibers
rather than their total amount, which is related to the histologic cov-
erage as assessed in our study, what might be more relevant in terms of
vascular invasion in NSCLC, as suggested elsewhere [42].
The rationale for examining proliferation was based on the in-
creased proliferation and survival through β1 integrin/FAK signaling
reported in TAFs and cancer cells cultured on hydrogels exhibiting
tumor-like rigidities [19], which mimicked the matrix stiffening that
arises from increased fibrillar collagen as reported in vivo and in vitro
[39,43]. However, we did not observe a significant correlation between
fibrillar collagens and the proliferation marker Ki-67. This negative
result was somewhat unexpected, considering that we did find a mar-
ginal association between PSR-BF% and the regional glucose uptake
marker SUVT, which is frequently used as a surrogate of cancer cell
proliferation [44]. Yet it is worth considering that enhanced SUVT has
been reported in fibrotic areas of idiopathic pulmonary fibrosis pa-
tients, which are rich in activated fibroblasts and fibrillar collagens but
void of cancer cells [45]. Therefore it is conceivable that the larger
Table 3
Multivariate analysis for predictors of survival.
α-SMA% > 10.5% PSR-BF% > 8% PSR-PL% > 3.3%
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
TAF marker
Low (ref.)a 1.00 1.00 1.00
High 1.89 (1.18-3.04) 0.009* 2.29 (1.33-3.98) 0.003* 1.94 (1.26-2.99) 0.003*
Tumor stage
IA1 (ref.) 1.00 1.00 1.00
IA2 0.22 (0.06-0.90) 0.035* 0.40 (0.11-1.52) 0.18 0.46 (0.12-1.76) 0.26
IA3 0.20 (0.05-0.76) 0.018* 0.31 (0.08-1.13) 0.076 0.34 (0.09-1.23) 0.10
IB 0.17 (0.05-0.63) 0.008* 0.27 (0.08-0.98) 0.047* 0.29 (0.08-1.02) 0.055
IIA 0.41 (0.11-1.62) 0.21 0.64 (0.17-2.43) 0.51 0.66 (0.17-2.50) 0.54
IIB 0.51 (0.15-1.73) 0.28 0.81 (0.24-2.69) 0.73 0.88 (0.26-2.93) 0.83
IIIA 1.03 (0.30-3.58) 0.96 1.75 (0.52-5.95) 0.37 1.89 (0.56-6.42) 0.31
IVA 6.58 (0.63-68.97) 0.12 10.5 (1.02-108.22) 0.048* 10.28 (1.00-105.77) 0.050
Card. comor.
No (ref.) 1.00 1.00 1.00
Yes 1.86 (1.22-2.86) 0.004* 1.82 (1.20-2.75) 0.005* 1.76 (1.16-2.65) 0.008*
NOTE:
Bold p-values indicate marginal significance (p < 0.1).
* p < 0.05 (Cox hazard proportional model).
a < 10.5% for α-SMA%,<8% for PSR-BF%,< 3.3% for PSR-PL%.
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SUVT observed here in patients with high PSR-BF% may partly reflect
the increased metabolic demands of collagen biosynthesis rather than
changes in cancer cell proliferation.
Unlike cancer cell proliferation and vascular invasion, we found a
marked association between all TAF activation markers and necrosis. In
agreement with our observation, tumour necrosis was reported to be an
independent prognostic marker in NSCLC using a cohort of 178 surgi-
cally resected cases [46]. Future studies are required to further validate
our observed association between stromal desmoplasia and tumor ne-
crosis as well as to elucidate the potential causes and consequences of
such association. However, it is worth noting that tumor necrosis is
commonly used as indicative of hypoxia [29], and that the link between
tumor hypoxia and aggressive phenotypes has been extensively docu-
mented [47]. Likewise, in vivo models of mammary tumors reported
that fibrotic tumors were also more hypoxic [48]. On the other hand,
hypoxia enhances collagen expression in vitro [49], suggesting that the
higher fibrillar collagen content found in samples with larger necrosis
could be partly a direct consequence of hypoxia. In addition, increased
fibrillar collagen has been also associated with collapsed microvessels
and impaired drug delivery due interstitial pressure built up in solid
tumors [50], thereby suggesting that a rise in stromal collagens could
enhance hypoxia per se. In support of this interpretation, the antifibrotic
drug nintedanib was shown to reduce the expression of fibrillar col-
lagens in activated TAFs in vitro [9], and to provide a survival benefit in
combination with the cytotoxic drug docetaxel in lung ADC [51]. Al-
together, these previous observations suggest that the increased histo-
logic coverage of fibrillar collagens could be both a cause and a con-
sequence of necrosis/hypoxia, and support that antifibrotic drugs
Fig. 3. Association of fibroblast activation markers with cancer-relevant biological processes.
Percentage of Ki-67 (marker of proliferation, left column), and necrosis (right column) for patients exhibiting activation markers below (low) or equal/greater (high)
than the corresponding threshold for α-SMA% (A), PSR-BF% (B) and PSR-PL% (C). Middle column shows the percentage of patients with each TAF marker equal/
greater than the corresponding cut-off according to their vascular invasion status. *, p < 0.05; **, p < 0.01; ***, p < 0.005.
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aiming to downregulate collagen expression could help reducing also
hypoxia in NSCLC.
5. Conclusions
In summary this study clarifies the prognostic value of α-SMA in
NSCLC, and identifies the histologic coverage of fibrillar collagens as-
sessed through PSR staining, particularly when imaged with polarized
microscopy, as a novel and independent stromal biomarker associated
with adverse prognosis in resected patients. Our analysis also identifies
patients with large fibrillar collagen content to exhibit higher risk of
recurrence and death, and reveal that they may benefit from a closer
follow-up and should be considered for adjuvant chemotherapy. Our
data also support a mechanistic relationship between collagen content
and necrosis/hypoxia.
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